Best Paper of the Session & Col.Rangachari Contestant

Dr. M. VANATHI

DR. NOOPUR GUPTA, Dr. (Mrs.) RADHIKA TANDON, DR. LIVIA KHAN

Abstract

Aim: To evaluate adjunct topical human immunoglobulin (IVIG) therapy in refractory inflammatory dry eye disease (DED).

Method: Prospective longitudinal comparative open-label study of adjunct topical human IVIG in DED. Study parameters included dry eye severity level, TBUT, Schirmer’s, corneal & conjunctival staining score (CFS & CSS), OSDI at baseline & 6-months followup (FU).

Result: In 47 of 56 eyes with 6month-FU, mean OSDI (69.5±14.3), Schirmer’s (8.8±8.5), CFS (5.2±3.8), CSS (5.8±3.4), FTBUT (3.7±3.2)] showed significant improvement at 3&6 month-FU [OSDI 0.003/<0.001, Schirmer’s <0.001/<0.001, CFS <0.001/0.0002, FTBUT <0.001/<0.001 & CSS 0.0627/0.008(improved at 6 months). There was reduction in topical lubricant & steroid therapy. Among controls – 42 eyes (21 patients), 38.09% (16 eyes) showed improvement at 6 month-FU.

Conclusion : Adjunct topical IVIG therapy is effective in controlling ocular surface inflammation & reducing steroid dependency in refractory inflammatory DED.

Full Text